Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 338Neoplasms, Plasma Cell 56Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Recurrence 50Lymphoma 48Leukemia 39Neoplasms 27Lymphoma, Mantle-Cell 27Burkitt Lymphoma 26Lymphoma, Large B-Cell, Diffuse 23Immunoglobulin Light-chain Amyloidosis 23Lymphoma, Non-Hodgkin 22Waldenstrom Macroglobulinemia 21Lymphoma, Follicular 17Leukemia, Lymphocytic, Chronic, B-Cell 16Hodgkin Disease 14Nausea 12Lymphoma, Extranodal NK-T-Cell 12Lymphoma, B-Cell, Marginal Zone 12Vomiting 11Smoldering Multiple Myeloma 11Prostatic Neoplasms 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Breast Neoplasms 11Renal Insufficiency 10Neoplasm Metastasis 9Lymphoma, Large-Cell, Immunoblastic 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 8Leukemia, Biphenotypic, Acute 7

Interventions

mogamulizumab 3Lenalidomide 2Gemcitabine 2peginterferon alfa-2b 1liposomal doxorubicin 1dolutegravir 1denileukin diftitox 1belinostat 1Zidovudine 1Tenofovir 1Taxes 1Panobinostat 1Paclitaxel 1Oxaliplatin 1Lomustine 1Irinotecan 1Introns 1Doxorubicin 1Dexamethasone 1Cytarabine 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1Alemtuzumab 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia-Lymphoma, Adult T-Cell × Dexamethasone × Clear all
NCT01626664 2024-04-25

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Kyowa Kirin Co., Ltd.

Phase 2 Completed
71 enrolled 15 charts
LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡